Regeneron Pharmaceuticals Financials - Benzinga

Regeneron Pharmaceuticals Inc

REGNNASDAQ

Trade with Public

Trade with Public

$788.04

-7.98-1%

가까이에: Sep 24, 5:00 PM EST

$788.04

-7.98-1%

프리마켓: 4:00 AM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 배당금 비교 옵션 주식 보고서

Regeneron Pharmaceuticals Financials

Regeneron Pharmaceuticals (REGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Regeneron Pharmaceuticals Q2 Adj. EPS $14.29 Beats $10.26 Estimate, Sales $4.291B Beat $3.816B Estimate

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $14.29 per share which beat the analyst consensus estimate of $10.26 by 39.28 percent. This is a 10.86 percent increase over earnings of $12.89 per

Benzinga Newsdesk

Stock Market Today: Dow, S&P 500, Nasdaq Futures Drop After UAE Nuclear Plant Strike— Regeneron Pharma, NextNRG, ServiceNow In Focus (UPDATED)

Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the story.

Rishabh Mishra

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Regeneron Pharmaceuticals (NASDAQ: REGN) reported strong Q1 earnings and a $3B share buyback. Analysts have mixed views on the stock.

Avi Kapoor

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.

Vandana Singh

Earnings Scheduled For April 29, 2026

Benzinga Insights

PRO
Regeneron Pharmaceuticals Q1 Adj. EPS $9.47 Beats $8.89 Estimate, Sales $3.605B Beat $3.483B Estimate

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $9.47 per share which beat the analyst consensus estimate of $8.89 by 6.52 percent. This is a 15.21 percent increase over earnings of $8.22 per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved